Advertisement

Drug Eruptions

  • Rita V. Patel
  • Gary Goldenberg
Chapter

Abstract

Cutaneous reactions are the most frequently occurring adverse reactions to drugs. These reactions can range from mild (two-thirds of cases) to life-threatening (one-third of cases) in the hospital setting [1, 2]. Distinguishing a mild versus a life-threatening reaction is challenging, yet critical, in the management of drug allergies. Cutaneous manifestations are frequently the earliest signs of a systemic drug allergy and can provide information on the severity and prognosis of an allergic reaction [3]. Numerous risk factors predispose patients to severe cutaneous drug reactions, including immunosuppression (especially infection with human immunodeficiency virus) [4] or mononucleosis [5], female gender [6], number of drugs being taken, and elderly age [7].

Keywords

Toxic Epidermal Necrolysis Drug Eruption Erythema Multiforme Serum Sickness Pustular Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol. 2011;71(5): 672–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Bigby M, et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Lubart R, et al. A novel explanation for the healing effect of the Er:YAG laser during skin rejuvenation. J Cosmet Laser Ther. 2011;13(1):33–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Battegay M, et al. Rash with amoxycillin-clavulanate therapy in HIV-infected patients. Lancet. 1989;2(8671): 1100.PubMedCrossRefGoogle Scholar
  5. 5.
    Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics. 1967;40(5):910–1.PubMedGoogle Scholar
  6. 6.
    Naldi L, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 1999;48(6):839–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol. 2000;136(7):849–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Thong BY, et al. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol. 2003;90(3): 342–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Bastuji-Garin S, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan HL, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1): 43–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Strom BL, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991;127(6):831–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Naldi L, et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126(8):1103–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Roujeau JC, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol. 1990;126(1):37–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Prendiville JS, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr. 1989;115(6):881–7.PubMedCrossRefGoogle Scholar
  15. 15.
    French LA, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bologina JL, Jorizzo JL, Rapini R, editors. Urticarias, erythemas, and pupuras. 2nd ed. Philadelphia, PA: Elsevier; 2008.Google Scholar
  16. 16.
    Wolkenstein PE, Roujeau JC, Revuz J. Drug-induced toxic epidermal necrolysis. Clin Dermatol. 1998;16(3): 399–408.PubMedCrossRefGoogle Scholar
  17. 17.
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19): 1272–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee A. Drug induced skin reactions. London: Pharmaceutical Press; 2006.Google Scholar
  19. 19.
    Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122(5):992–1000.PubMedCrossRefGoogle Scholar
  20. 20.
    Chung WH, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Schopf E, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6): 839–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Mockenhaupt M, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30(10): 2234–40.PubMedGoogle Scholar
  23. 23.
    Devi K, et al. Carbamazepine–the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol. 2005;71(5):325–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Mockenhaupt M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Levi N, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2): e297–304.PubMedCrossRefGoogle Scholar
  26. 26.
    Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85(2):131–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lebargy F, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Revuz J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 1999;40(3):131–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.PubMedCrossRefGoogle Scholar
  31. 31.
    Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011;39(6):1521–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Bastuji-Garin S, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia-Doval I, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Oplatek A, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27(1):26–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Dunn K, Edwards-Jones V. The role of acticoat with nanocrystalline silver in the management of burns. Burns. 2004;30 Suppl 1:S1–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Wolf R, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23(2): 171–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Brown KM, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25(1):81–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3): 206–18.PubMedGoogle Scholar
  39. 39.
    Campione E, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83(6):430–2.PubMedGoogle Scholar
  40. 40.
    Prins C, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Shortt R, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25(3):246–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Valeyrie-Allanore L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4): 847–53.PubMedCrossRefGoogle Scholar
  43. 43.
    Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am. 2010;94(4):727–42. x.PubMedCrossRefGoogle Scholar
  44. 44.
    Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Kano Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Magina S, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207(1):33–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Gueudry J, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Power WJ, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102(11):1669–76.PubMedGoogle Scholar
  49. 49.
    Roujeau JC, et al. Reporting adverse drug reactions. Lancet. 1985;2(8466):1244.PubMedCrossRefGoogle Scholar
  50. 50.
    Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol. 1984;120(6):721–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Wolf R, et al. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Clin Dermatol. 2005;23(3):311–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Descamps V, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137(3): 301–4.PubMedGoogle Scholar
  53. 53.
    Fiszenson-Albala F, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Clark RA, et al. The vast majority of CLA  +  T cells are resident in normal skin. J Immunol. 2006;176(7): 4431–9.PubMedGoogle Scholar
  55. 55.
    Schaerli P, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med. 2004;199(9):1265–75.PubMedCrossRefGoogle Scholar
  56. 56.
    Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Picard D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46):46ra62.PubMedCrossRefGoogle Scholar
  58. 58.
    Eshki M, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67–72.PubMedCrossRefGoogle Scholar
  59. 59.
    Saida S, et al. A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergol Int. 2010;59(1):83–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12): 1373–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Gupta A, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 1992;51(1):56–67.PubMedCrossRefGoogle Scholar
  62. 62.
    Spanou Z, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919–27.PubMedCrossRefGoogle Scholar
  63. 63.
    Chung WH, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRefGoogle Scholar
  64. 64.
    Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6–11.PubMedCrossRefGoogle Scholar
  65. 65.
    Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60. quiz 161-2.PubMedGoogle Scholar
  66. 66.
    Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy. 2007;27(10): 1425–39.PubMedCrossRefGoogle Scholar
  67. 67.
    Beltraminelli HS, et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152(4):780–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9(4): 322–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4(8):561–72.PubMedCrossRefGoogle Scholar
  70. 70.
    Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Sidoroff A, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case–control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–96.PubMedCrossRefGoogle Scholar
  72. 72.
    Pirquet SV. Serum sickness. Baltimore: Wilkins; 1951.Google Scholar
  73. 73.
    Lawley TJ, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311(22):1407–13.PubMedCrossRefGoogle Scholar
  74. 74.
    Vincent C, Revillard JP. Antibody response to horse gamma-globulin in recipients of renal allografts: relationship with transplant crises and transplant survival. Transplantation. 1977;24(2):141–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Clark BM, et al. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy. 2006;26(5):705–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med. 1971;134(3):7–18.PubMedGoogle Scholar
  77. 77.
    King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health. 2003;39(9):677–81.PubMedCrossRefGoogle Scholar
  78. 78.
    Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin. 2007;25(2):245–53. viii.PubMedCrossRefGoogle Scholar
  79. 79.
    Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol. 2006;6:3.PubMedCrossRefGoogle Scholar
  80. 80.
    Vial T, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992;26(7–8):910–4.PubMedGoogle Scholar
  81. 81.
    Molldrem JJ, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699–705.PubMedCrossRefGoogle Scholar
  82. 82.
    Hommes DW, van Deventer SJ. Infliximab therapy in Crohn’s disease: safety issues. Neth J Med. 2003;61(4):100–4.PubMedGoogle Scholar
  83. 83.
    D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44(7):1717–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol. 2007;34(2):430–3.PubMedGoogle Scholar
  85. 85.
    Lundquist AL, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl. 2007;13(5):647–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Bielory L, et al. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol. 1985;13(3):411–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Joubert GI, et al. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol. 1999;6(4):197–201.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Department of DermatolgoyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations